JULY, 20225 IN MY OPINIONCXO INSIGHTS1915222408HOW SMALL PHARMA, WORKING WITHIN A GLOBAL PHARMA, CAN BENEFIT FROM ONE PHARMACOVIGILANCE SYSTEMTHE DISREGARDED ENABLER OF INNOVATIONENHANCING COMPLIANCE THROUGH PROCESS LEADERSHIPMai Huang, M.D., Executive Director, Drug Safety and Pharmacovigilance, Avanir Pharmaceuticals (NASDAQ : AVNR)By Billy Ingram, Director, Lean Product Development, InterfaceLine Sandberg, Vice President Global Quality, Centrient Pharmaceuticals12SPEED, SAFETY AND SCALABILITY: AN INTEGRATIVE APPROACH TO DRUG DEVELOPMENTLinda Cherry,Vice President andDoug Niven, PhD, executive director,Syneos Health (NASDAQ: SYNH)TOP 10EMERGING CLEANROOMCOMPANIES IN EUROPE - 2022Offering High-Quality HVAC Equipment and Cleanroom TechnologiesKLIMAOPREMARESANITEC35Ali Ismail, CEOMOORE ENVIRONMENTAL32David Donohoe, CEOFEATURED COMPANYMr. Sergio Galosi, CEO 40CHALLENGES AND OPPORTUNITIES FOR AI IN DRUG DISCOVERYRobert J. Prill,Director, Data Science and AI, Computational Biology and Data Sciences andYong Yue, Senior Director, Computational Biology andData Sciences, Ferring Research Institute, Inc.27PARTNERING WITH A CDMO FOR SUCCESSFUL LATE PHASE BIOLOGIC DRUG PRODUCT DEVELOPMENT AND LAUNCHRoman Mathaes,Head of Pharmaceutical Services andCristina Grigore, Technical Proposals Manager,Lonza(SWX: LONN)33HOW TO MANAGE REGULATORY COMPLIANCEScott Cleve,Vice President Regulatory Operations andCompliance, Bluebird bio (NASDAQ: BLUE)TRANSFORMING PHARMACOVIGILANCE USING TECHNOLOGY ­ HELP OR HYPE?Sebastian Horn,Vice President, Head of Global PatientSafety & Pharmacovigilance, Teva Pharmaceuticals
< Page 4 | Page 6 >